source
- AI data emerges as a key hurdle in biopharma partnership dealsAs drug discovery becomes more intricate, the data used to train AI models is turning into a valuable asset in biopharma transactions. Companies are now negotiating not just drug candidates but the…
- Arrowhead's gene-silencing therapy shows strong results in two late-stage triglyceride trialsArrowhead Pharmaceuticals reported positive data from its lipid-lowering gene-silencing candidate Redemplo in two late-stage studies. The results suggest the therapy effectively reduces triglyceri…